In 2013, Zhang et al.[41] reported for the first time an ex vivo expansion of CTCs for breast cancer, also demonstrating those CTCs to have metastasis initiating properties in the brain when expressing a specific genetic signature (the aforementioned Her2+/EGFR+/HPSE+/Notch1+). This evidence concerns the gene ERBB2 and breast carcinoma.